TYW2 and neoplasm: Targeted drugs (such as TRMT12 activators) can be developed to address the modification abnormalities caused by low TRMT12 expression, restore its normal expression to correct tRNA modification imbalance, and enhance the killing effect of paclitaxel on tumor cells.